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Abstract
Motivation: There is recent interest in using gene expression data to contextualize findings from
traditional genome-wide association studies (GWAS). Conditioned on a tissue, expression quanti-
tative trait loci (eQTLs) are genetic variants associated with gene expression, and eGenes are genes
whose expression levels are associated with genetic variants. eQTLs and eGenes provide great
supporting evidence for GWAS hits and important insights into the regulatory pathways involved
in many diseases. When a significant variant or a candidate gene identified by GWAS is also an
eQTL or eGene, there is strong evidence to further study this variant or gene. Multi-tissue gene ex-
pression datasets like the Gene Tissue Expression (GTEx) data are used to find eQTLs and eGenes.
Unfortunately, these datasets often have small sample sizes in some tissues. For this reason, there
have been many meta-analysis methods designed to combine gene expression data across many
tissues to increase power for finding eQTLs and eGenes. However, these existing techniques are
not scalable to datasets containing many tissues, like the GTEx data. Furthermore, these methods
ignore a biological insight that the same variant may be associated with the same gene across
similar tissues.
Results: We introduce a meta-analysis model that addresses these problems in existing methods.
We focus on the problem of finding eGenes in gene expression data from many tissues, and show
that our model is better than other types of meta-analyses.
Availability and Implementation: Source code is at https://github.com/datduong/RECOV.
Contact: eeskin@cs.ucla.edu or datdb@cs.ucla.edu
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Expression quantitative trait loci (eQTLs) studies find eQTLs, which
are genetic variants associated with gene expression, and eGenes,
which are genes whose expression levels are associated with at least
one genetic variant. eQTL studies are related to traditional genome-
wide association studies (GWAS) which find variants associated
with disease.
Both eQTL studies and GWAS focus on single nucleotide poly-
morphisms (SNPs). Many SNPs found by GWAS are located in
intergenic regions, and their relationship to the disease phenotype is
often not obvious. Gene expression is an intermediate phenotype be-
tween a causal SNP and a disease (Huang et al., 2014). Thus, eQTL
studies may provide biological insights into the mechanism through
which disease occurs. If a significant SNP identified by GWAS is
found to be an eQTL, there is a strong evidence to further study the
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variant. For this reason, top hits in GWAS that are also eQTLs are
of special interest. In fact, recent GWAS have confirmed that many
disease-causing variants are eQTLs (Albert, 2016; Liu et al., 2016;
Nieuwenhuis et al., 2016). Similarly, genes near GWAS-significant
SNPs that are identified as eGenes may warrant further study as can-
didate causal genes. Thus, eQTL studies provide great supporting
evidence for GWAS results and important insights into the regula-
tory pathways involved in many diseases.
The underlying approach behind eQTL studies and GWAS is the
same. In an eQTL study, one performs association tests between the
genotype data and the gene expression (instead of disease statuses) to
identify variants that are associated with the gene expression. eQTLs
and eGenes may be specific to only one or a group of tissues, as a gene
is not always uniformly expressed in every tissue. For example, SNPs
associated with schizophrenia have been found to be eQTLs in only the
brain tissues, indicating that schizophrenia affects how the brain func-
tions (Fromer et al., 2016). For this reason, there have been recent
large-scale studies to collect gene expression data in many tissues, such
the Genotype-Tissue Expression (GTEx) project (The GTEx
Consortium, 2015). This GTEx dataset contains gene expression data
in 44 tissues and genotypes of 5 million SNPs for over 300 individuals.
To find eQTLs from the GTEx data and other multi-tissue data-
sets, one can apply the traditional tissue-by-tissue (TBT) approach,
in which a separate eQTL study is done for each tissue. However,
many tissues do not have enough samples to detect SNPs that are
weakly associated with the gene expressions. To address this issue,
there have been many efforts in developing different types of meta-
analysis, which gather data from many tissues to increase the total
sample size and power to detect eQTLs. Two notable methods are
Meta-Tissue and eQTLBma. Both have been shown to outperform
the traditional TBT method (Flutre et al., 2013; Sul et al., 2013).
Meta-Tissue and eQTLBma have an important limitation that
reduces their applicability to large gene expression datasets such as
the GTEx data. Both methods are computationally intensive and
should used for datasets containing at most 10 or 20 tissues, respect-
ively (Flutre et al., 2013; Sul et al., 2013). Meta-Tissue uses both lin-
ear mixed models (LMMs) and fixed (or random) effects meta-
analysis to combine data from many tissues. Meta-Tissue must esti-
mate the variance components in its LMM setup for every pair of
variant and gene expression; thus, its runtime is impractical when
there are thousands of genes or too many tissues (Sul et al., 2013).
eQTLBma uses a Bayesian approach that considers all possible com-
binations of tissues in which a SNP is an eQTL. This setup corresponds to
2T configurations where T is the number of tissues, making the method
infeasible when T is 44 like in the GTEx data (Flutre et al., 2013).
As an alternative to Meta-Tissue and eQTLBma, the GTEx con-
sortium used a meta-analysis software called Metasoft, introduced
by Han and Eskin (2011). Metasoft is equivalent to Meta-Tissue
without the LMM setup (Han and Eskin, 2011, 2012). Metasoft ex-
tends the random effects (REs) meta-analysis model; this extended
model is named RE2 (Han and Eskin, 2011).
However, Meta-Tissue, eQTLBma and RE2 assume that a SNP
has independent effect on a given gene’s expression in each tissue.
This ignores the fact that the same SNP tends to have similar effects
in related tissues (The GTEx Consortium, 2015).
Recently, Acharya et al. (2016) introduced a method that
amends this shortcoming in Meta-Tissue, eQTLBma and RE2. The
model developed by Acharya et al. (2016) requires genotype and
gene expression data for each individual in each tissue. Their imple-
mentation in R, using the JARGUAR library, requires loading all
these data into memory. When there are many genes and tissues, this
approach can be memory intensive.
In this article, we present a novel meta-analysis method named
RECOV. Unlike Meta-Tissue and eQTLBma, RECOV is applicable
to large gene expression datasets and can analyze all 44 tissues in
the GTEx data. Like JARGUAR, RECOV considers the biological
insight that a variant may have similar effects on a gene across tis-
sues. However, unlike JARGUAR, RECOV needs only the summary
statistic (i.e. SNP effect and its variance) at each SNP in each tissue
and not the complete genotype and gene expression data for each in-
dividual. RECOV is based on the RE2 meta-analysis framework and
uses a covariance (COV) matrix to explicitly model the correlation
of a SNP effect on the same gene’s expression in similar tissues.
In the Section 2, we describe RECOV in detail and demonstrate
how it can be used to identify eGenes from eQTL studies in more
than one tissue. In the Results section, we use simulated datasets to
show that RECOV has correct false positive rate (FPR). We then
apply RECOV to real multi-tissue expression data from the GTEx
dataset. Our results show that RECOV detects more eGenes than
previous RE2 and TBT methods.
2 Materials and methods
We begin by introducing the notations in this article. We use x 2 Rn
to specify a vector x with dimension n, and Z 2 Rnm to specify a
matrix Z with dimension n  m. We use xi to denote the ith element
in x, and likewise, Zij to specify entry ij in Z. We denote an item k in
the set K by k 2 K, and a set fa1 . . . aKg indexed by k by using
fakgk2K, where the subscript k 2 K is omitted whenever the context
is clear. The size of the set K is denoted as jKj.
2.1 Detecting one eGene via an eQTL study
2.1.1 eQTL study in one tissue
We begin with an eQTL study in one tissue t. An eQTL study finds
every eQTL associated with the expression level of a specific gene g.
To do this, the study tests each variant v in the set V against the ex-
pression of g in a sequential fashion. To set up the problem, suppose
we represent the gene expression for m individuals in tissue t as a
vector q 2 Rm, and we want to find the effect of variant v on g. Let s
2 Rm be the standardized genotypes of this v. The eQTL study as-
sumes the following model
q ¼ bvgtsþ vgt (1)
where  2 Rm is the vector of sampling errors   N 0; r2 I
 
, and bvgt
2 R is the true effect size of the variant v on g in tissue t (Eskin,
2015). The estimate bvgt of the true value bvgt can be computed
using the basic least squares equation bvgt ¼ argminbvgt jjq bvgtsjj22
(Abraham and Ledolter, 2006). This solution is
bvgt ¼ s>s
 1
s>q where bvgt  N bvgt; s>s
 1
r2
 
(2)
By using Equation (2) and writing the null hypothesis H0: bvgt ¼ 0,
one can do a hypothesis test to assert if v has an effect on g. To do
this test, compute the estimate br2vgt of r2vgt by
br2vgt ¼ 1m 1
Xm
i¼1 qi  bvgtsi
 2
(3)
and estimate the variance dvgt of bvgt by
dvgt ¼ s>s
 1br2vgt (4)
then compute the p-value pvgt ¼ p value bvgt
 
(Abraham and
Ledolter, 2006; Eskin, 2015). If pvgt is less than some significance
level, then we reject H0: bvgt ¼ 0, and conclude that v is an eQTL of
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g in tissue t. When many variants are tested, we must apply a mul-
tiple testing correction; for example, one can apply Bonferroni cor-
rection by using the threshold a=jVj where a is the significance level
for the whole family of tests. The Bonferroni correction is conserva-
tive when there is linkage disequilibrium (LD) in set V. There exist
other methods that can handle LD better than the Bonferroni correc-
tion (Darnell et al., 2012; Joo et al., 2014, 2016; Hormozdiari et al.,
2015).
2.1.2 Using an eQTL study in one tissue to discover one eGene
Because an eQTL study tests each variant v 2 V against gene g in a
tissue t, from a single eQTL study we have a set of p-values
fpvgtgv2V . The minimum pgt ¼ minv2Vfpvgtg is defined to be the
observed eGene statistic at gene g in tissue t (The GTEx
Consortium, 2015). Define apgt ¼ p value pgt
 
to be the eGene
p-value (The GTEx Consortium, 2015). The eGene p-value
depends on two important factors: the number of variants jVj,
and the LD of the variants. In practice, apgt is computed by doing a
permutation test (Sul et al., 2015; Duong et al., 2016). In brief, in
the kth permutation, one would permute the gene expressions
among the individuals, and compute a new p
kð Þ
gt ¼ minv2Vfp kð Þvgtg. apgt
is the ranking of the observed pgt with respect to the density
created from many p
kð Þ
gt . If its eGene p-value apgt is less than
some desired threshold, one can then conclude that g is an eGene
in tissue t.
2.2 TBT analysis to find one or many eGenes
When there are genotype-tissue expression data from many tissues,
TBT analysis is the standard method to find eGenes (Sul et al., 2013;
The GTEx Consortium, 2015). TBT tests whether or not the gene
has at least one eQTL in each tissue by examining each tissue indi-
vidually. Suppose the gene is expressed in T tissues. Then TBT per-
forms T eQTL studies (one test in each tissue). The null hypothesis
is that the gene is not an eGene in any tissue. This hypothesis is
equivalent to saying that no eQTL is found for this gene in any
tissue.
Three layers of multiple testing correction are required since
TBT performs one test per gene in each tissue. The first layer of
multiple testing correction is applied within a tissue and corrects
for LD of the variants tested against the gene. This correction can
be done by using the permutation test to compute the eGene
p-value for the gene in the tissue (Duong et al., 2016; Sul et al.,
2013, 2015).
The second layer of multiple testing correction adjusts for the
fact that we may test more than one gene within a tissue. For ex-
ample, the GTEx pilot study tested thousands of genes within one
tissue, and then transformed eGene p-values into eGene q-values to
control for this multiple testing (Dabney et al., 2010; The GTEx
Consortium, 2015). This second layer of multiple testing correction
is not needed if only one gene is tested in each tissue.
The third layer of multiple testing correction takes into account
the fact that one gene is tested T number of times (once per tissue)
(Sul et al., 2013). In this article, we apply Bonferroni correction so
that the false-positive threshold for any eGene q-value in each tissue
is a=T, where a is 5% for example. In this layer, other multiple test-
ing correction methods such as the Benjamini-Hochberg correction
can be used instead of the Bonferroni correction. However, this
paper focuses on the meta-analysis model, and measuring the per-
formances of various multiple testing correction methods is beyond
its scope.
2.3 Meta-analysis models for combining eQTL studies
across tissues
We motivate the application of meta-analysis for combining eQTL
studies across tissues. An eQTL is defined not only with respect to a
gene, but also with respect to the tissue in which the gene expression
is measured. eQTL studies of the same gene have been analyzed sep-
arately at the tissues level (The GTEx Consortium, 2015). We can
better detect the effect of a variant on the gene by combining eQTL
results across many tissues and modeling the relatedness of the effect
sizes of one variant among the tissues.
When using meta-analysis to find many eGenes, it is important
to emphasize that one would need only two layers of multiple testing
correction. The first layer is applied within a gene to correct for LD
because one tests many variants against the gene. The second layer
is applied at the gene level because there is usually more than one
gene being tested.
We define the notations to be used later. Suppose we have T
eQTL studies (one study per tissue) that test the association of a
variant v at a gene g. As before, denote the effect of this variant in
the study (i.e. tissue) t as bvgt, where bvgt is computed using
Equation (2). Denote the variance of bvgt in the study t as dvgt where
dvgt is computed using Equation (4). Let bvg 2 RT contain the ef-
fects in these T studies, so that bvg ¼ bvg1 bvg2    bvgT
 >
. Let
Dvg ¼ diag dvg1 . . .dvgT
 
.
2.3.1 REs and the RE2 model
The maximum likelihood procedure in the RE model assumes that bvg
has the form (Han and Eskin, 2011; Thompson and Sharp, 1997)
bvg ¼ kvg þ vg (5)
The random sampling errors vg are estimated from the data and
assumed to be vg  N 0;Dvg
 
. kvg 2 RT in the RE model is a ran-
dom variable, i.e. kvg  N lvg1; s2vgI
 
with lvg 2 R and s2vg 2 Rþ.
Here the number 1 denotes a vector with all entries equal to 1. The
effect kvg is thus known as the random effect. lvg is the common
true underlying effect that all the studies inherit. The term s2vg is the
heterogeneity among the effects of the variant in T tissues.
Clearly, bvg comes from the distribution
bvg  N lvg1; s2vgIþDvg
 
(6)
The traditional RE model assumes that if the effect of the variant
does not exist in any tissue, then lvg ¼ 0. However, it has been
shown that this traditional null hypothesis does not yield optimal
statistical power in detecting eQTLs (Han and Eskin, 2011, 2012).
For this reason, the RE2 model assumes a different null hypothesis,
that if the effect of the variant does not exist in any tissue, then lvg
¼ 0 and s2vg ¼ 0. The fact that s2vg ¼ 0 is a result of lvg ¼ 0 because
when the effect does not exist, its variance must not exist (Han and
Eskin, 2011, 2012; Kang et al., 2014). We will compare our method
against the RE2 model.
The null hypothesis H0 in RE2 is
H0 : lvg ¼ 0 s2vg ¼ 0 (7)
The log likelihood ratio for testing this hypothesis becomes
llrvg ¼ 2 log
suplvg ;s2vg L bvgjlvg; s2vg
 
L bvgjlvg ¼ 0; s2vg ¼ 0
  (8)
The function L denotes the likelihood function of the random vari-
able bvg. The numerator suplvg ;s2vg L bvgjlvg; s2vg
 
may be estimated
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using numerical methods or other heuristic methods. Here, we apply
the Nelder-Mead method, which is a heuristic derivative-free search
method.
In finding the supremum, one implicitly enforces s2vg  0. Due to
this restricted parameter space, the asymptotic density of the likeli-
hood ratio is an average of a v21 and v
2
2 (Self and Liang, 1987; Han
and Eskin, 2011). To find the p-value of this likelihood ratio when
T is large, one can use this asymptotic density.
Otherwise, one may compute the likelihood ratio p-value by creat-
ing a density of likelihood ratios under the null hypothesis and rank-
ing the observed likelihood ratio with respect to this density. This null
density is made by sampling many instances of bvg using Equation (6)
with lvg ¼ s2vg ¼ 0, and computing their corresponding llrvg. If the
p-value of llrvg is significant, then v is an eQTL with respect to g in at
least one tissue. Because we have 44 tissues in the GTEx data, we will
use the asymptotic distribution of the likelihood ratio.
2.3.2 RECOV: REs model with a COV term
Here we present an extension to the RE model. We first
discuss the COV term. Equation (5) of the RE model assumes kvg
 N lvg1; s2vgI
 
so that the effects of variant v toward gene g are in-
dependent across the tissues. However, tissues from the same body
part are similar; in fact, many eQTLs are found to be consistent
among many tissues (Flutre et al., 2013). From this observation, we
must acknowledge that kvg  Nðlvg1;RvgÞ where Rvg is not diag-
onal. The term Rvg 2 RTT models the COV of effect sizes of
v among tissues conditioned on the gene g. The matrix Rvg contains
T  T unknown parameters which are to be estimated. In practice,
one has to assume a simpler form for Rvg. Here, we assume
Rvg  cvgUvg. The matrix Uvg is estimated from the data. The term
cvg  0 is an unknown scaling constant and is optimized jointly with
the mean of regression coefficient lvg.
In this article, we compute the Uvg at each variant-gene pair as
follows. Denote Bg ¼ b1g b2g    bjVjg
 
so that Bg 2 RTjVj. A
column in Bg contains the effects of a variant in 44 tissues. To avoid
reusing the data when testing a single SNP, we remove its effects in
the 44 tissues when estimating its COV term. To do this, we divide
all cis-variants of g into 10 separate segments according to their
physical locations on the chromosome, and use the 9 segments that
do not contain v to compute Uvg. In particular, denote Bvg as the
matrix Bg without the effect sizes of the variants that belong to the
same segment as v. Uvg can be estimated as Uvg ¼ BvgB>vg (after
proper scaling is applied to Bvg). This computation is similar to
how one would compute a kinship matrix using the genotype matrix
(Eskin, 2015). In this scheme, we observe that the variants in strong
LD with v are also removed, so that there are fewer vectors in Bvg
that resemble bvg when computing Uvg. This further helps reducing
the problem of data reusing. Supplementary Table S2 shows that by
removing SNPs in the same segment as v, we retain fewer SNPs that
are in strong LD with v.
Now, we are ready to introduce this COV term Uvg to the RE
model. We extend the RE model so that when testing a variant v
against gene g, we have
bvg ¼ kvg þ vg (9)
where
kvg  N lvg1; cvgUvg
 
vg  N 0;Dvg
 
(10)
Like before, the matrix Dvg is known because it contains the
observed variances of the SNP effects estimated by Equation (4).
This form for Dvg is standard in meta-analysis (Thompson and
Sharp, 1997). We now have
cov bvg
  ¼ cvgUvg þDvg (11)
bvg  N lvg1; cov bvg
  
(12)
The null hypothesis that v does not affect g in all T tissues is
H0 : lvg ¼ 0 cvg ¼ 0 (13)
The alternative hypothesis implies that v has an effect in at least one
of the T tissues.
Under this setting, the log likelihood ratio to test the hypothesis
becomes
llrvg ¼ 2 log
suplvg ; cvg L bvgjlvg; cvg
 
L bvgjlvg ¼ 0; cvg ¼ 0
  (14)
Like in the RE model, in finding the supremum in the alternative,
one enforces cvg  0. Due to this restricted parameter space, the
asymptotic density of the likelihood ratio is an average of a v21 and
v22. Alternatively, one can compute the empirical p-value of this like-
lihood ratio with a permutation test. In any case, if the p-value of
the likelihood ratio is significant, then v is an eQTL with respect to
g in at least one tissue.
2.4 Using meta-analysis of eQTL in many tissues to
identify eGenes
In practice, a set of variants V is tested against g. Here we describe
how one can combine the meta-analysis result at each variant v 2 V
to determine if g is an eGene.
Define pvg ¼ p value llrvg
 
so that from many variants, we
have the set of p-values fpvggv2V . The observed statistic at gene g is
pg ¼ minv2Vfpvgg. To determine if pg is significant, one needs to
compute its eGene p-value apg (The GTEx Consortium, 2015). To
control for multiple testing when LD exists between the variants,
one can compute apg using a permutation test (Duong et al., 2016;
Sul et al., 2015; The GTEx Consortium, 2015). The permutation
test creates a distribution of the observed pg under the null hypoth-
esis, which can then be used to compute the eGene p-value apg of pg.
This permutation test can be done as follows. Let K be the num-
ber of permutations. In the kth permutation, permute the gene ex-
pression of g among the individuals in each of the T tissues so that
there are T permuted datasets. This permutation reflects the hypoth-
esis that the gene is not an eGene in any tissue. Next, redo the meta-
analysis at each variant v 2 V so that a new p kð Þg ¼ minv2Vfp kð Þvg g is
computed. apg is the fraction of times the observed pg is less than
p
kð Þ
g . The gene g is an eGene in at least one tissue if its eGene p-value
apg is below some threshold a.
In the pilot GTEx analysis, a set of genes G is being tested at
once, so that one has a set aG ¼ fapggg2G. To control for the family
wise error rate, one can apply Bonferroni correction to get the
threshold a=jGj. Any gene g 2 G with apg < a=jGj is an eGene in at
least one of the T tissues.
2.4.1 Estimating eGene p-value
The permutation test above must be performed at every pair of vari-
ant v 2 V and gene g 2 G in a tissue t. The entire permutation test
requires KjVjjGjT permuted datasets, which is time consuming.
Here, we introduce an alternate method to estimate the eGene p-
value. In essence, the permutation test estimates a function f that
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maps a test statistic to its p-value. There is evidence that the correl-
ation of test statistics at two variants is equal to their LD (Han
et al., 2009). This holds true when the test statistics are effect sizes
(Han et al., 2009).
In our meta-analysis, to properly estimate the eGene p-value apg ,
we must consider the effect of LD in the set of variants V on the
observed statistic at each variant v. At each variant, it does not mat-
ter whether we treat its llrvg or its pvg as the observed statistic, be-
cause the likelihood ratio and its p-value are two equivalent entities
for two reasons. First, the likelihood ratio of each variant v has the
same distribution and degree of freedom. Second, the p-value func-
tion is 1-to-1 and strictly monotone. Thus, having a null density for
the maxv2Vfllrvgg is equivalent to having a null density for the min-
imum pg.
We empirically find that on average the correlation of the likeli-
hood ratios at any two variants is roughly equal to their LD; that is,
on average cor llrug; llrvg
   LD u; vð Þ for any variant u; v 2 V
(Fig. 1). For this reason, any function f that accounts for LD and
maps an observed test statistic of a gene into an eGene p-value
would be applicable in our case. We can use such a function to con-
vert the observed test statistics pg at the gene g to eGene p-value apg
without doing the permutation test. Each gene g has its own LD
structure and requires its own function f, because the cis-variants of
each gene are non-identical.
We apply MVN-EGENE to estimate the function f for each
gene. MVN-EGENE is a software that tests if a gene is an eGene in
one tissue. MVN-EGENE is designed so that one does not need to
do the permutation test when estimating an eGene p-value. MVN-
EGENE is unable to simultaneously consider more than one tissues,
as would a meta-analysis would.
To compute the function f at a gene, we apply MVN-EGENE at
that gene in a tissue (Sul et al., 2015). We assume that the LD does
not change much between tissues, and it does not matter much
which particular tissue is chosen, as long as it has many samples.
In MVN-EGENE, the test statistic for a gene is the most signifi-
cant effect size taken over all cis-variants. The p-value of this test
statistic depends on the LD of the cis-variants. Instead of doing a
permutation test to compute this p-value, MVN-EGENE simulates
data under the null hypothesis using a multivariate normal
distribution. In brief, in one simulation, MVN-EGENE samples the
effect sizes of the cis-variants of a gene in a tissue using zero as the
mean effect and LD as the COV matrix. In this simulation, the most
significant effect among these effect sizes is taken to be the test stat-
istic at the gene. After many simulations, one can create a null distri-
bution for the observed test statistic. One can easily convert an
effect size into a p-value using a normal distribution. By having a
null density of the most significant effect size taken over all the vari-
ants, one also has the null density of the minimum p-value taken
over all the variants. This null density of the minimum p-value in
MVN-EGENE properly handles LD at the gene. Here, we use this
distribution of minimum P-values as our null density to convert the
observed minimum likelihood ratio p-value pg to its eGene P-value
apg in both RECOV and RE2.
2.4.2 Estimating genomic control
In the GTEx dataset and other multi-tissue gene expression datasets,
the same individual may provide samples for many tissues (Fig. 2).
Sharing of samples from the same individuals among tissues is
known to inflate the FPR in a meta-analysis (Han et al., 2016).
Before testing whether the RECOV outcome is affected by the fact
that tissues share individuals, we test if RECOV inflates the FPR
when the data is absolutely free of any spurious statistical associ-
ation. These signals can be due to LD, shared individuals in tissues,
batch effects, or correlated expressions of the same gene (or between
genes) across tissues. It is important to mention that in the real
GTEx data, batch effects have been dealt with by the GTEx consor-
tium by applying PEER factors on the gene expression in each tissue
(The GTEx Consortium, 2015). Subsection 2.4.1 above describes
how RECOV and RE2 handle LD in the variants. We now describe
how we use a genomic control (GC) factor to remove the effect of
shared individuals in the tissues from the meta-analysis results. This
GC factor is clearly data dependent as different datasets will require
different GC values.
Here, we focus on finding the GC factor for the GTEx data. To
do this, we simulate two types of datasets and compare their behav-
iors. The first type does not contain any spurious statistical signals.
The second type contains only signal due to sharing of samples
among the tissues, and the number of people shared between pairs
of tissues is taken from the GTEx data. Our goal is to apply RECOV
and RE2 to the GTEx data; to avoid data reusing, the SNPs and the
gene expressions in both types of datasets are simulated and thus are
independent of the values in the GTEx data.
When there is not any spurious statistical association in the data,
any alternative hypothesis must be rejected more often than the null
hypothesis. We simulate data to demonstrate that RECOV does not
inflate FPR in this case. In each simulated dataset, the number of in-
dividuals per tissue is taken from the GTEx data, but we do not let
tissues share individuals. We generate 1000 SNPs at various minor
allele frequency (MAF) without LD, and a random gene expression
in each tissue. We generate gene expressions where the expression of
the same gene is not correlated between any two tissues. We com-
pute the p-value of the likelihood ratio at each SNP using both
RECOV and RE2 model. We repeat this simulation 1000 times to
obtain 1 000 000 p-values each for RECOV and RE2. The histo-
grams of these p-values in both RECOV and RE2 indicate that the
null hypothesis is more favored than the alternative hypothesis (Fig.
3A and B).
To measure the effect strictly caused by shared individuals, we
simulate datasets as above, but now allow tissues to share individ-
uals. The number of people shared between pairs of tissues is taken
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Fig. 1. Correlation for the likelihood ratios of a pair of cis-variants versus their
LD. Denote corðllru ; llrv Þ as the correlation for the likelihood ratios of variants
u and v over all genes where both are cis-SNPs. Empirically, corðllru ; llrv Þ is
close to the LD of u and v. To show this, we randomly select many pairs of
cis-SNPs from the gene ENGS00000204219.5 that also appear together in at
least two other genes. These pairs are then grouped into bins by their LD (bin
width 0.05). We compute the likelihood ratio for each SNP in each pair over
all the genes in which they are cis-variants. Using these likelihood ratios, we
estimate corðllru ; llrv Þ for the pair u, v. We average corðllru ; llrv Þ over all pairs
u, v in each LD bin. We then plot the absolute value of this average against
the LD value. The identity line is shown in red. Plots for additional pairs
chosen from other genes are shown in Supplementary Figure S1
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from the GTEx data. In each simulation, we compute the likelihood
ratio p-values at 1000 SNPs, and repeat the simulation 1000 times
to obtain 1 000 000 P-values. We observe that these p-values shift
toward 0 when the tissues share samples that are from the same indi-
viduals (Fig. 3C and D). In this case, we estimate the RECOV and
RE2 GC factor to be 1.2947 and 1.1045, respectively. These GC
factors are used to remove the effect caused by shared individuals in
tissues that may inflate the FPR. To compute a GC factor, one con-
verts the median of the observed p-values into a chi-square statistic,
then finds a multiplying factor to scale this new statistic to a chi-
square random variable that has p-value at 0.50 (Devlin and
Roeder, 1999).
3 Results
3.1 RECOV controls FPR
When using any meta-analysis method to find an eGene, one needs
to apply the method at every cis-variant of the specified gene in
order to determine if that gene has at least one eQTL. Thus, the glo-
bal FPR of RECOV and RE2 depends on the FPR at a single cis-
variant. For this reason, we measure the FPR of RECOV and RE2 at
a single variant.
To obtain the FPR at one variant, we simulate 1000 datasets for
a single variant under the null hypothesis where the variant is not
associated with the gene expression in any of 44 tissues. The MAF
of the SNP is randomly chosen and kept the same in all 1000 data-
sets. Then in each dataset, the genotype for this SNP and the gene
expression are simulated independently of the values in the GTEx
data.
To make the simulated data more realistic, we first let each tissue
have the same number of individuals as in the GTEx data, and each
pair of tissues have the same number of shared samples as in the
GTEx data. Second, we set expression levels of the same gene from
the same individual to be correlated with an average correlation of
0.5 across tissues, using the sampling method described in (Sul et al.,
2013). This correlation of expression can occur when the tissues of
an individual have been exposed to the same environmental factors.
In each of the 1000 datasets, we estimate the effect size and vari-
ance of this single variant on the gene expression in each tissue.
RECOV and RE2 take these effect sizes and variances and produce a
meta-analysis p-value for this variant. The GC factor estimated in
Subsection 2.4.2 is used to transform this p-value in each simulation.
This removes only the effect of shared individuals, which is not ex-
plicitly modeled in RECOV and RE2. The FPR of this single variant
is the fraction of times its transformed p-values are significant.
We repeat this experiment for 1000 independent variants, so
that we have 1000 measures of FPR for RECOV and RE2. We use
the significance level of 0.05 (a ¼ 0.05). We find that RECOV at-
tains correct FPR for the majority of variants tested. In RECOV, the
median FPR among the 1000 variants is 0.05, and the 75 and 95%
quantiles are 0.06 and 0.09. In RE2, the median FPR is 0.05, and
the 75 and 95% quantiles are 0.07 and 0.10. These results demon-
strate that RECOV and RE2 control the FPRs in a realistic setting.
3.2 RECOV discovers more eGenes in GTEx data
We apply RECOV, RE2 and TBT to the real multi-tissue eQTL
dataset from the GTEx consortium. We use GTEx Pilot Dataset V6
released on 12 January 2015. The GTEx consortium has performed
RNA-seq on 44 tissues from hundreds of individuals, and we select
15 336 genes that have expression data in all 44 tissues. The consor-
tium has already applied PEER factors to every gene expression in
each tissue to remove any batch effects (The GTEx Consortium,
2015). For genotype data, we use the GTEx imputed genotype data
that contains 5 million SNPs for each individual. Like in the original
GTEx pilot study, for each gene, we use its cis-SNPs, which are
defined to be located within 1Mb from its transcription start site
(The GTEx Consortium, 2015). Not all variants are genotyped in
every tissue, because the 44 tissues contain samples from different
individuals. We use only cis-variants that are genotyped in all 44 tis-
sues. The median number of cis-variants tested per gene is 3744.
For each of the 15 336 genes, we apply RECOV, RE2, and TBT
to every cis-SNP. For each cis-SNP of a gene, our test statistic is the
log likelihood ratio (for RECOV and RE2) or SNP-effect (for TBT).
These test statistics are converted into p-values by using a chi-square
distribution (for RECOV and RE2) or normal distribution (for
Fig. 2. Shared individuals among the 44 tissues in the GTEx dataset. Degree
of sample sharing between two tissues is measured using the Jacquard
index
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Fig. 3. (A) RECOV and (B) RE2 applied to datasets where the tissues do not
share individuals. (C) RECOV and (D) RE2 applied to datasets where the tis-
sues share individuals
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TBT). These p-values are then transformed using the GC factors to
remove the effect of shared individuals in the tissues. Finally, the
most significant p-value among all cis-variants is converted into an
eGene p-value by method in 2.4.1 (for RECOV and RE2) or by
EGENE-MVN (for TBT).
After computing the eGene p-values for 15 336 genes, we use
Bonferroni correction to control for multiple testing correction at
5% level to identify significant eGene p-values; thus, each gene has a
significance threshold of 0.05/15 336.
Figure 4A shows the Venn diagram of the numbers of eGenes
found by TBT, RE2 and RECOV. The majority of tested genes are
found to be candidate eGenes. This is expected because there are
many tissues tested. It is likely that a gene contains at least one
eQTLs in some tissue, which significantly increases the total number
of eGenes detected. Both RE2 and RECOV find more candidate
eGenes than TBT. This result agrees with previous findings where
applying meta-analysis to multi-tissue datasets yields better outcome
than the simple TBT approach (Flutre et al., 2013; Sul et al., 2013).
RECOV detects the highest number of eGenes among the three
methods. Out of the 15 336 genes tested, RECOV finds that 81.40%
of those genes are eGenes while TBT and RE2 find 61.90 and
78.45% of genes are eGenes, respectively. This shows that our ap-
proach detects 3% more eGenes than RE2 and about 20% more
eGenes than TBT.
Next, we apply each method to a case study in order to under-
stand the circumstances where one method outperforms the other
two. We begin with the simple TBT method. In Figure 4A, there are
252 genes detected only by the TBT method. Previous publications
have reported TBT to be the most powerful option to detect genes
with eQTLs that are found in only one tissue (Sul et al., 2013; The
GTEx Consortium, 2015). In the TBT method, one analyzes each
tissue independently, and is able to determine the number of tissues
in which a gene is an eGene. In our result, out of these 252 genes,
225 are eGenes in only 1 tissue, 25 are in 2 tissues, and only 2 are in
3 tissues. This finding agrees with Figure 2 in Sul et al. (2013).
Of the 452 genes discovered by only RECOV, the average
RECOV eGene p-value is 8:52E9 61:51E8
 
; whereas the
average RE2 eGene p-value is 4:18E3 62:85E2
 
. To understand
why RECOV discovers genes that are not found by TBT and
RE2, consider the protein-coding gene CABLES1 (Ensembl id
ENSG00000134508.8) which is only detected by RECOV. From the
GTEx portal, CABLES1 is expressed mostly in brain tissues, yet it
does not have any brain-specific eQTLs. RECOV is a meta-analysis
method that pools samples across tissues to increase signals of
eQTLs. Thus, when the sample size per tissue is small enough that
eQTL signals may be undetected, RECOV outperforms TBT. Unlike
RE2, the meta-analysis of RECOV considers correlation of the cis-
variants across the tissues; thus RECOV would be better than RE2 if
CABLES1 has a consistent correlation pattern. This is indeed the
case (Fig. 4B). CABLES1’s RECOV and RE2 eGene p-value are 4:94
E13 and 5E5, respectively.
Of the 88 genes discovered by only RE2, the average RE2 eGene
p-value is 1:15E8 61:44E8
 
; whereas the average RECOV eGene
p-value is 1:85E4 62:32E4
 
. We suspect that these 88 genes are
genes with eQTLs in multiple tissues. However, due to low sample
size, these eQTLs signals may be undetected or do not produce an
eGene q-value less than the significance threshold in TBT analysis.
As a case study, consider the protein-coding gene GALNT11
(Ensembl id ENSG00000178234.8) which is detected by only RE2.
Like CABLES1, GALNT11 is expressed mostly in the brain tissues
(The GTEx Consortium, 2015). Unlike CABLES1, GALNT11 has
eQTL signals in the frontal cortex brain tissue, but these signals pro-
duce an eGene q-value of 0.0189 which is higher than the TBT sig-
nificance threshold. In this case, a meta-analysis approach is more
suitable because it combines data from many tissues to improve the
eGene p-value. GALNT11’s cis-variants have correlated effect sizes
across the brain tissues, but this pattern does not stand out from the
rest of the tissues when compared with that of CABLES1 (Fig. 4C).
For this reason, GALNT11’s RECOV p-value is higher than its RE2
p-value (3:50E4 versus 7:08E8). RE2 may also have better
performance than RECOV in cases where the cis-variants do not
have an obvious correlation pattern across the 44 tissues. As an ex-
ample, consider the pseudogene RP11-34P13.16 (Ensembl id
ENSG00000269981.1), which is not tissue-specific (The GTEx
Consortium, 2015). The effect sizes of its cis-variants appear to be
randomly correlated (Fig. 4D), and its RECOV and RE2 p-values
are 1:50E4 and 1:37E8, respectively. Altogether, these attributes
may have caused the different results produced by RECOV and
RE2.
4 Discussion
In this article, we introduce a new REs meta-analysis method named
RECOV. Our approach is motivated by the insight that the same
SNP may have similar effect on the same gene in related tissues. We
explicitly model these phenomena by adding a COV matrix to the
existing RE2 model introduced by Han and Eskin (2011). When
applied to the GTEx data, RECOV controls the FPR at the SNP
level. More importantly, using no additional data, RECOV finds
3% more eGenes than the TBT and RE2 methods.
A B C D
Fig. 4. (A) Venn diagram of the numbers of eGenes found by TBT, RE2 and RECOV. (B) The correlation of SNP-effects for the gene ENSG00000134508.8 in 44
tissues (tissue names are omitted). The correlation is computed by using the matrix Bg in Subsection 2.3.2 where the formula is BgB
>
g (after proper scaling and re-
moval of nearby SNPs). Black box indicates the brain tissues. ENSG00000134508.8 is found to be an eGene by only the RECOV method. The correlation of SNP-ef-
fects for gene (C) ENSG00000178234.8 and (D) ENSG00000269981.1 in 44 tissues (tissue names are omitted). ENSG00000178234.8 and ENSG00000269981.1 are
found to be eGenes by only the RE2 method
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RECOV scales well to large numbers of tissues compared with
previous meta-analysis methods for gene expression data. For ex-
ample, Meta-Tissue and eQTLBma can only handle up to 10 and 20
tissues, respectively (Flutre et al., 2013; Sul et al., 2013). RECOV
also requires only the summary statistics for the SNP effect on the
gene expression in each tissue. These summary statistics are often
readily available in gene expression data. Thus, unlike the model by
Acharya et al. (2016), RECOV requires minimal data preparation.
RECOV, and the RE2 it extends, require optimizing two param-
eters in the log likelihood ratio. These unknowns are the mean effect
size and the scaling factor for the COV matrix, both of which can be
estimated using efficient heuristic methods. We note that the TBT
method avoids this optimization. This is a speed-performance trade-
off. This study and others show that the meta-analysis approach is
better than TBT when applied to multi-tissue data (Acharya et al.,
2016; Flutre et al., 2013; Sul et al., 2013;). Unlike TBT, RECOV
does not provide information about the specific subset of tissues in
which the gene is an eGene. This problem is inherent to all meta-
analysis methods, which only test whether a gene is an eGene in at
least one tissue.
Next, we address our use of the GC factor for RECOV. The GC
factor is traditionally used to correct for inflation due to population
structure in classic GWAS, but in this paper, we use it to correct for in-
flation from any unmodeled source. We show that this inflation is due
to tissues containing samples from the same individuals. This problem
of sample sharing is not the same as the problem of population struc-
ture in GWAS (Han and Eskin, 2011, 2012). The value of the GC fac-
tor depends on the choice of the COV matrix Uvg in the model. As
shown in this article, when Uvg ¼ I for RE2 the GC factor is 1.1045,
whereas when Uvg ¼ BvgB>vg for RECOV the GC factor is 1.2947.
RECOV is a general framework for meta-analysis that can be
used with any COV matrix. The COV matrix used in this article
(described in Subsection 2.3.2) reflects our assumptions about the
behavior of the same SNP in different tissues. Namely, we assume a
SNP has correlated effects on a gene’s expression across tissues.
There are many ways to select this COV matrix, and other options
may better fit different assumptions about the data. For example, if
we instead assume the same SNP has correlated effects on the ex-
pressions of different genes across the tissues, we can estimate Uvg
by combining information from neighboring genes of g, using know-
ledge from a gene–gene interaction network. The problem of select-
ing the most suitable COV matrix for RECOV is a rich topic for
future work.
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